|
|
|
|
|
Melanoma Epitopes
Melanoma, a malignant tumor that arises in melanocytes, is the most deadly of all skin cancers. Although it accounts for only 4% of all skin cancer cases, melanoma is the leading cause of skin cancer deaths (1). Several antigens expressed in melanoma cells and recognized by T cells have been identified and used in developing immunization approaches for tumor regression (2). These include: MART-1/Melan-A , gp100 , Tyrosinase , p15, TRP-1 and beta-catenin (2).
AnaSpec is committed to providing the world’s most comprehensive and innovative collection of peptide solutions for cancer research. This month our spotlight focus is on several newly released melanoma immunodominant epitopes and their analogs.
[Ala26]-Melan-A/MART-1 (26-35)
Melan-A/MART-1 (27-35)
Melan-A, MART 1 (26-35)
[Leu27]-Melan-A, MART 1 (26-35)
Melan-A/MART-1 (24-34)
MELAN-A/MART-1 (32-40)
Melanocyte Associated Antigen gp 100 (17-25)
Melanocyte Associated Antigen gp100
gp100 (476-485)
gp100 (570–579)
gp100 (457-466)
gp100 (614–622)
gp100 (639–647)
gp100 (619–627)
gp100 (178-187)
Tyrosinase (146-156)
Tyrosinase (206-214), T9206
[Asp370]-Tyrosinase (368-376)
Tyrosinase (1-9)
(Asn370) tyrosinase (368–376)
Tyrosinase (192-200)
Tyrosinase (56-70)
Tyrosinase (450-462)
Tyrosinase (243-251), core nonamer sequence
Tyrosinase (240-251)
To request AnaSpec’s 2006-2008 Peptides catalog, click here
References:
1. American Cancer Society: Cancer Facts and Figures—2006. Atlanta GA: American Cancer Society, 2006.
2. Rosenberg, SA. J. National Cancer Inst. 88, 1635 (1996).
|
|
|
|
|
|
|
|
|
|
|
|
|
